<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349995</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10278</org_study_id>
    <nct_id>NCT04349995</nct_id>
  </id_info>
  <brief_title>Amplatzer PFO Occluder Post-marketing Surveillance Study</brief_title>
  <acronym>PFO PMS Jpn</acronym>
  <official_title>Amplatzer PFO Occluder Post-marketing Surveillance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Amplatzer PFO Occluder post-marketing clinical use surveillance study is&#xD;
      to observe the frequency, type and degree of adverse device effects and adverse events in&#xD;
      order to assure the safety of the new medical device, and to collect safety and efficacy&#xD;
      information for evaluating the results of the clinical use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the Ministerial Ordinance on Good Post-marketing Study Practice for Medical Device,&#xD;
      the Surveillance will register patients with patent foramen ovale (PFO) who have experienced&#xD;
      a PFO-related cryptogenic cerebral infarction (including diagnosed paradoxical cerebral&#xD;
      embolism) or transient ischemic attack (determined by positive head imaging such as DWI) in&#xD;
      whom an Amplatzer PFO Occluder implant was attempted (Marketing Approval No.&#xD;
      30100BZX00024000, date May 28, 2019, hereinafter referred to as &quot;PFO occluder&quot;).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">May 28, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>device- or procedure related SAE rate</measure>
    <time_frame>up to 30 Days</time_frame>
    <description>device- or procedure related serious adverse events (SAEs) through 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PE, DVT and ischemic stroke and atrial fibrillation rate</measure>
    <time_frame>beyond 30 days through 3 years</time_frame>
    <description>rate of pulmonary embolism (PE), deep vein thrombosis (DVT), ischemic stroke and atrial fibrillation beyond 30 days through 3 years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effective PFO closure</measure>
    <time_frame>At 1 year</time_frame>
    <description>Effective closure of the PFO at 1 year</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>PFO - Patent Foramen Ovale</condition>
  <arm_group>
    <arm_group_label>Amplatzer PFO Occluder</arm_group_label>
    <description>Percutaneous PFO Closure using Amplatzer PFO occluder</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amplatzer PFO Occluder</intervention_name>
    <description>Percutaneous PFO closure using Amplatzer PFO Occluder</description>
    <arm_group_label>Amplatzer PFO Occluder</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be considered registered upon insertion of the Amplatzer PFO Occluder&#xD;
        delivery system into the body&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Refer to Amplatzer PFO occluder IFU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refer to Amplatzer PFO occluder IFU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Abbott Medical Japan LLC</name>
      <address>
        <city>Mita</city>
        <state>Minato</state>
        <zip>108-6304</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

